- Home
- ENSC vs DRMA Comparison
ENSC vs DRMA Comparison
Compare ENSC & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- DRMA
- Stock Information
- Founded
- ENSC 2003
- DRMA 2014
- Country
- ENSC United States
- DRMA United States
- Employees
- ENSC N/A
- DRMA N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- DRMA Health Care
- Exchange
- ENSC Nasdaq
- DRMA Nasdaq
- Market Cap
- ENSC 4.9M
- DRMA 4.5M
- IPO Year
- ENSC N/A
- DRMA 2021
- Fundamental
- Price
- ENSC $2.22
- DRMA $0.60
- Analyst Decision
- ENSC
- DRMA Strong Buy
- Analyst Count
- ENSC 0
- DRMA 1
- Target Price
- ENSC N/A
- DRMA $3.00
- AVG Volume (30 Days)
- ENSC 230.3K
- DRMA 94.5K
- Earning Date
- ENSC 08-13-2025
- DRMA 08-06-2025
- Dividend Yield
- ENSC N/A
- DRMA N/A
- EPS Growth
- ENSC N/A
- DRMA N/A
- EPS
- ENSC N/A
- DRMA N/A
- Revenue
- ENSC $6,224,081.00
- DRMA N/A
- Revenue This Year
- ENSC N/A
- DRMA N/A
- Revenue Next Year
- ENSC $1,381.48
- DRMA N/A
- P/E Ratio
- ENSC N/A
- DRMA N/A
- Revenue Growth
- ENSC 256.35
- DRMA N/A
- 52 Week Low
- ENSC $1.62
- DRMA $0.57
- 52 Week High
- ENSC $14.67
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- ENSC 49.53
- DRMA 29.24
- Support Level
- ENSC $2.02
- DRMA $0.57
- Resistance Level
- ENSC $2.30
- DRMA $0.63
- Average True Range (ATR)
- ENSC 0.14
- DRMA 0.04
- MACD
- ENSC 0.02
- DRMA -0.01
- Stochastic Oscillator
- ENSC 43.40
- DRMA 11.55
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.